The Era of Personalized Cancer Therapeutics

  Isabel Levy & Seema Bachoo Glossary Adoptive T cell transfer, Allosteric site, Clonal expansion, CRISPR-Cas9, DNA, DNA sequencing, EGFR, ‘Gain-of-function’ mutation, Genome, Genomic Instability, GTPase, GDP, GTP, Kinase, ‘Loss-of-function’ mutation, MAPK signaling pathway, Mutation, Oncogene/Proto-oncogene,  Personalized Cancer Medicine, PI3K pathway, RAS, TP53 gene, Tumor suppressor gene   Background Cancer: a disease of the genome […]

What is Digital Health and how is it revolutionizing healthcare?

Olivia Crossley   Keywords Arrhythmia, Artificial intelligence, Blood Pressure, Consultant, Digital health, Electrodes, EEG, ECG, FDA, Machine Learning, Side effects, Telemedicine, Ultrasound, UK’s General Data Protection Regulation, Wearable technologies Digital technologies are electronic devices that analyze and store different kinds of information. These technologies have revolutionized how we communicate, learn, and shop. Now, digital devices […]

Advanced Therapies Congress, 24-25 May, 2022, ExCel, London

On the 24th of May, 2022, PMM team members, Xuanqi Song and Sam Jarada, attended the Advanced Therapies Congress held at the London ExCeL. The Advanced Therapies Congress explored, defined, and attempted to tackle the main challenges currently being faced when it comes to the development of patient access to advanced therapy medicinal products (ATMP). […]

How immunotherapy can improve colorectal cancer prognosis

Aaron Logsdon   Abbreviations CAR, chimeric antigen receptor; CAR-T, chimeric antigen receptor T lymphocyte therapy; CRC, colorectal cancer; DCR, disease control rate; dMMR, mismatch repair-deficient; FDA, US Food and Drug Administration; ICI, immune checkpoint inhibition; MMR, mismatch repair genes; MSI-H, high microsatellite instability; MSS, microsatellite stable; OR, objective response; pMMR, mismatch repair proficient; Treg, T […]

Huntington’s disease: prevention and current innovations in treatment

Huntington’s disease: prevention and current innovations in treatment Jenny ChatzigerouHuntington’s disease (HD) is a genetic neurodegenerative disorder that was first described in 1872 by the physician George Huntington,1 in his seminal paper ‘On Chorea’.  Huntington described the condition as a hereditary, progressive, adult-onset disease that caused patients to suffer from a range of cognitive, motor, […]